HPLC Method Development and Validation of S(-)-Carvedilol from API and Formulations


A simple chiral HPLC method was developed and validated for quantification of S(-)-Carvedilol in Active Pharmaceutical Ingredient (API) and marketed tablet formulation of racemic Carvedilol. Chiral resolution of enantiomers of Carvedilol was achieved on Phenomenex Lux-cellulose–4 (250 mm × 4.6 mm; 5 μ particle size) chiral column by using a mobile phase, Isopropanol and n-Heptane (60:40 v/v), at a flow rate of 1.0 ml/min and by employing UV detection at 254 nm wavelength. The method was validated according to the ICH guidelines and was proved to be specific, linear, precise and accurate for the analysis of S(-)-Carvedilol.

Share and Cite:

Swetha, E. , Vijitha, C. and Veeresham, C. (2015) HPLC Method Development and Validation of S(-)-Carvedilol from API and Formulations. American Journal of Analytical Chemistry, 6, 437-445. doi: 10.4236/ajac.2015.65043.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Phuong, N.T., Lee, B.J., Chol, J.K., Kang, J.S. and Kwon, K. (2004) Enantioselective Pharmacokinetics of Carvedilol in Human Volunteers. Archives of Pharmacal Research, 27, 973-977.
[2] Gagyi, L., Gyeresi, A. and Kilar, F. (2008) Role of Chemical Structure in Stereoselective Recognition of Beta-Blockers by Cyclodextrins in Capillary Zone Electrophoresis. Journal of Biochemical and Biophysical Methods, 70, 1268-1275.
[3] Lamprecht, G., Gruber, L., Staschitzky, K. and Lindner, W. (2002) Enantioselective Analysis of (R)- and (S)-Carvedilol in Human Plasma by High Performance Liquid Chromatography. Chromatographia, 56, S25-S29.
[4] Oldham, H.G. and Clarke, S.E. (1997) In Vitro Identification of the Human Cytochrome P450 Enzymes Involved in the Metabolism of R(+)- and S(-)-Carvedilol. Drug Metabolism and Disposition, 25, 970-977.
[5] Nakajima, T., Ma, J., Iida, H., Iwasawa, K., Jo, T., Omata M., et al. (2003) Inhibitory Effects of Carvedilol on Calcium Channels in Vascular Smooth Muscle Cells. Japanese Heart Journal, 44, 963-978.
[6] Jia, H. and Chan, H.K. (2010) Comparing the Effects of Carvedilol Enantiomers on Regression of Established Cardiac Hypertrophy Induced by Pressure Overload. Laboratory Animal Research, 26, 75-82.
[7] Takekuma, Y., Yagisawa, K. and Sugawara, M. (2012) Mutual Inhibition between Carvedilol Enantiomers during Racemate Glucuronidation Mediated by Human Liver and Intestinal Microsomes. Biological and Pharmaceutical Bulletin, 35, 151-163.
[8] Bhushan, R. and Dixit, S. (2012) Enantioresolution of Five β-Blockers by Reversed-Phase High Performance Liquid Chromatography Using Fifteen Chiral Derivatizing Reagents Having Amino Acids or Their Amides as Chiral Auxiliaries on a Cyanuric Chloride Platform. Biomedical Chromatography, 26, 239-246.
[9] Yang, E., Wang, S., Kratz, J. and Cyronak, M.J. (2004) Stereoselective Analysis of Carvedilol in Human Plasma Using HPLC/MS/MS after Chiral Derivatization. Journal of Pharmaceutical and Biomedical Analysis, 36, 609-615.
[10] Zakrzewski-Jakubiaka, M., de Denusb, S., Leblancc, M.-H., Whiteb, M. and Turgeon, J. (2010) Enantioselective Quantification of Carvedilol in Human Plasma by HPLC in Heavily Medicated Heart Failure Patients. Journal of Pharmaceutical and Biomedical Analysis, 52, 636-641.
[11] Spahn, H., Henke, W., Langguth, P., Schloos, J. and Mutschler, E. (1990) Measurement of Carvedilol Enantiomers in Human Plasma and Urine Using S-Naproxen Chloride for Chiral Derivatization. Archiv der Pharmazie, 323, 465-469.
[12] Peccinini, R.G., Ximenes, V.F., Cesarino, E.J. and Lanchote, V.L. (2008) Stereoselective Analysis of Carvedilol in Human Plasma and Urine Using HPLC after Chiral Derivatization. Biopharmaceutics & Drug Disposition, 29, 280-288.
[13] Wang, S., Cyronak, M. and Yang, E. (2007) Does a Stable Isotopically Labeled Internal Standard Always Correct Analyte Response? A Matrix Effect Study on a LC/MS/MS Method for the Determination of Carvedilol Enantiomers in Human Plasma. Journal of Pharmaceutical and Biomedical Analysis, 43, 701-707.
[14] Clohs, L. and McErlane, K.M. (2003) Comparison between Capillary Electrophoresis and High Performance Liquid Chromatography for the Stereoselective Analysis of Carvedilol in Serum. Journal of Pharmaceutical and Biomedical Analysis, 31, 407-412.
[15] Saito, M., Kawana, J., Ohno, T., Kaneko, M., Mihara, K., Hanada, K., et al. (2006) Enantioselective and Highly Sensitive Determination of Carvedilol in Human Plasma and Whole Blood after Administration of the Racemate Using Normal-Phase High-Performance Liquid Chromatography. Journal of Chromatography B, 843, 73-77.
[16] Medvedovici, A., Albu, F., Georgita, C., Sora, D.I., Galaon, T., Udrescu, S., et al. (2007) Achiral-Chiral LC/LC-FLD Coupling for Determination of Carvedilol in Plasma Samples for Bioequivalence Purposes. Journal of Chromatography B, 850, 327-335.
[17] Clohs, L. and McErlane, K.M. (2001) Development of a Capillary Electrophoresis Assay for the Determination of Carvedilol Enantiomers in Serum Using Cyclodextrins. Journal of Pharmaceutical and Biomedical Analysis, 24, 545-554.
[18] Behn, F., Michels, S., Laer, S. and Blaschke, G. (2001) Separation of Carvedilol Enantiomers in Very Small Volumes of Human Plasma by Capillary Electrophoresis with Laser-Induced Fluorescence. Journal of Chromatography B, 755, 111-117.
[19] ICH Harmonised Tripartite Guideline (2005) Validation of Analytical Procedures: Text and Methodology Q2(R1). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, 2005, 1-13.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.